PolyPeptide Group AG (SWX:PPGN)
Switzerland · Delayed Price · Currency is CHF 22.50
+0.45 (2.04%)
Jul 21, 2025, 5:30 PM CET
PolyPeptide Group AG Company Description
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India.
It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies.
The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices.
PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
PolyPeptide Group AG
| Country | Switzerland |
| Founded | 1952 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,362 |
| CEO | Juan Gonzalez |
Contact Details
Address: Neuhofstrasse 24 Baar, 6340 Switzerland | |
| Phone | 41 435 020 580 |
| Website | polypeptide.com |
Stock Details
| Ticker Symbol | PPGN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | CH1110760852 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Juan Jose Gonzalez | Chief Executive Officer |
| Marc Augustin | Chief Financial Officer |
| Jens Fricke | Director of Global Operations |
| Rene Vestergaard | Director of Corporate Finance |
| Olivier Ludemann-Hombourger | Director of Global Innovation and Technology |
| Michael Staheli | Head of Investor Relations and Corporate Communications |
| Christina Del Vecchio | Chief Legal Officer and Corporate Secretary |
| Andreas Liese | Corporate Compliance Manager |
| Trishul Shah MS | Interim Director Global Sales and Marketing |
| Monika Casanova | Chief Human Resources Officer |